

ARC-15088-1

11

PATENT

**Reply To Examiner's Remarks**

The Examiner appears to require submission of a substitute specification, including recitation of sections that are not included in the originally filed specification. A substitute specification is filed herewith, adding a recitation of the (applicable or inapplicable) sections "Cross Reference To Related Applications," "Statement Regarding Federally Sponsored Research Or Development," "Incorporation By Reference Of Material Submitted On A Compact Disc," "Reference To A Microfiche Appendix," and "Sequence Listing," together with several renamed sections. This substitute specification contains no changes other than recitation of the (inapplicable) sections "Cross Reference To Related Applications," "Statement Regarding Federally Sponsored Research Or Development," "Incorporation By Reference Of Material Submitted On A Compact Disc," "Reference To A Microfiche Appendix," and "Sequence Listing" and the several renamed sections.

Claims 1-27 and 29-38, as amended herein, and new claims 39-41 are pending for consideration.

The Examiner objects to use of the word "region" in the second line of claim 16. Claim 16 is amended to replace this word by the word "region."

The Examiner notes that confusion between "method" and "system" occurs in the preamble and/or body of claims 1 and 28. Claims 1 is amended, and claim 28 is canceled, herein to remove this confusion. The Applicants thank the Examiner for noting this confusion, which was unintentional.

The Examiner objects to appearance of the phrases "selected biological insert," "selected cage thickness," "selected molecule," "selected molecules," "selected active biological substance," "selected cell culture," "selected active biological substance," "selected bead," "selected ambient medium," "selected chemical," "selected active substance," "selected triggering agent," "second selected time," "second selected triggering agent," "selected medical device," "selected activation time," "selected signal," and "selected control time," in claims 1, 3, 6, 9, 11, 19, 23, 27, 30, 31, 33, 34, 35 and 37, asserting that use of the term

ARC-15088-1

12

PATENT

“selected, without more, does not convey any clear limitation of the term to which this adjective is applied. Claims 1, 3, 6, 9, 11, 19, 23, 27, 30, 31, 33, 34, 35 and 37 are amended herein to remove the adjective “selected” or to provide an additional limitation.

The Examiner objects to use of the phrase “insulin-containing compound” in claim 21, asserting that insulin is a compound and would not be contained in another compound. This is incorrect. A compound, such as acetyl salicylic acid, which is an active ingredient in aspirin, is a compound and is often included in other compounds, such as pain reducers. However, claim 21 is amended herein to recite a “compound that includes insulin.”


The Examiner objects to use of the phrase(s) “comprising estimating a degree ... interprets this degree” in claim 28. Claim 28 is canceled herein.

The substitute specification and substitute Abstract of the Disclosure are presented on pages supplemental pages 1-15 and supplemental page 24 herein, respectively, in order to preserve the original numbering of the pages of the application.

The Applicants have responded to the Examiner’s comments and objections and have extensively amended the claims. The Applicants request that the Examiner proceed with further examination of this patent application.

Date: 23 February 2005

Respectfully Submitted,



John Schipper

Patent representative for Applicants